Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

Technology appraisal guidance
Reference number: TA283
Published: 22 May 2013
Last updated: 20 May 2024

Macular oedema (retinal vein occlusion) - ranibizumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Macular oedema (retinal vein occlusion) - ranibizumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Macular oedema (retinal vein occlusion) - ranibizumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
11 April 2013
(518.08 Kb 30 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 08 April 2013